{"entity":{"id":"idea-regional-radiopharmacy-network","kind":"idea","name":"In-house hospital radiopharmacy compounding to cut dose waste","aka":[],"tldr":"Radioactive treatments lose strength every day as they travel from a central factory to the hospital, so by the time a dose arrives some of its power has decayed away. Installing compact, automated dose-preparation equipment inside individual hospitals, so they compound the treatment themselves from bulk material, could cut that wasted radioactivity and get treatment to more places.","summary":"Lutetium-177 decays with a roughly 6.6-day half-life, so every day a finished dose spends in transit from a centralised commercial manufacturer to a treating hospital is activity permanently lost, and the further a treatment centre is from that manufacturer, the more waste and scheduling risk it faces. An alternative model is for individual hospitals to compound doses themselves from bulk shipments of the raw isotope, using compact automated synthesis units designed to fit inside an existing hospital radiopharmacy hood. A 2025 paper describes one such unit, 'MiniLu', a cassette-based, self-contained radiosynthesis platform that achieved greater than 99% radiochemical purity and about 95% final dose yield for two PSMA-targeting therapeutic ligands, explicitly designed for hospital-resident compounding rather than centralised manufacturing.\n\nThis decentralisation is already happening at small scale in some markets: a 2026 market analysis reports that hospital radiopharmacy units in Mexico City, Monterrey and Guadalajara have grown from an estimated 3-5 to 8-12 sites capable of onsite GMP labelling since 2022, explicitly to reduce logistical waste from short-half-life lutetium-177, with domestically compounded lutetium-177 dotatate capturing an estimated 20-30% of treatment volume in that market. The joint EANM/SNMMI/IAEA guide to setting up a theranostics centre documents the radioactive-material licensing and radiation-safety steps a hospital needs to run in-house compounding.\n\nThis is a narrower, single-institution version of the regional cyclotron-hub policy idea already in this graph (a national or multi-country network of shared hubs); this idea is specifically about individual hospitals building their own point-of-care compounding capability, which trades a larger upfront capital and licensing cost per site for less dependence on shipping schedules and less decay-related waste. No controlled study quantifying the waste or access benefit of this decentralised model over centralised commercial dose manufacturing was found.","asOf":"2026-09-22","links":[{"label":"Optimization of the radiosynthesis of PSMA-targeting drugs using a cassette-based platform (MiniLu) (PMC, 2025)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12623512/"},{"label":"Peptide Receptor Radionuclide Therapy (PRRT) Market in Mexico (IndexBox market report, 2026)","url":"https://www.indexbox.io/store/mexico-peptide-receptor-radionuclide-therapy-prrt-market-analysis-forecast-size-trends-and-insights/"},{"label":"Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center (Journal of Nuclear Medicine)","url":"https://jnm.snmjournals.org/content/63/12/1836"},{"label":"The growth of radiotherapeutics: Addressing supply chain complexity (pharmaphorum, 2026)","url":"https://pharmaphorum.com/rd/growth-radiotherapeutics-addressing-supply-chain-complexity"}],"tags":["radiopharmacy","supply chain","access"],"related":["idea-reg-regional-radiopharmacy-hubs","radiopharmacy-network","radiopharmaceutical-gmp-release","therapy-isotope-supply-chain","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Installing automated, hospital-resident radiopharmacy compounding units that prepare short-half-life doses (lutetium-177 or actinium-225 ligands) on demand from bulk isotope shipments will reduce dose waste from radioactive decay in transit and improve treatment access outside major metropolitan centres, compared with relying solely on centralised commercial dose manufacturing and next-day shipping.","rationale":"A described automated cassette-based synthesis unit ('MiniLu') demonstrates that hospital-hood-compatible, hospital-resident compounding of lutetium-177 PSMA ligands can achieve greater than 99% purity and about 95% yield, comparable to centralised manufacturing. Market data from Mexico show hospital radiopharmacy sites capable of onsite GMP labelling roughly doubling since 2022, explicitly to reduce Lu-177 decay waste, and now handling an estimated 20-30% of treatment volume in that market — real-world evidence the model is being adopted, though no controlled comparative study of waste reduction or access improvement was found.","test":"A controlled before/after study across a multi-site hospital system, comparing dose waste (activity discarded to decay or scheduling failures), turnaround time and patient access (drive time to nearest treatment site) before and after installing in-house automated compounding units at 3-5 hospitals, against a comparable set of hospitals continuing to rely on centralised commercial dose supply.","maturity":"early-clinical","actor":"industry","cost":"large","horizonYears":7},"route":"/ideas/idea-regional-radiopharmacy-network/","neighbours":{"idea":[{"id":"idea-reg-regional-radiopharmacy-hubs","kind":"idea","name":"Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes","route":"/ideas/idea-reg-regional-radiopharmacy-hubs/"}],"technology":[{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/"},{"id":"radiopharmacy-network","kind":"technology","name":"Radiopharmacy and cyclotron networks","route":"/technologies/radiopharmacy-network/"},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/"}],"isotope":[{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}]}}